Momentum Is Strong For Nektar Therapeutics (NASDAQ: NKTR)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Nektar Therapeutics is $171.54M. A total of 1.32 million shares were traded on the day, compared to an average of 1.62M shares.

In the most recent transaction, ROBIN HOWARD W sold 20,033 shares of NKTR for 0.68 per share on Feb 20 ’24. After the transaction, the President & CEO now owns 879,889 company shares. In a previous transaction on Feb 20 ’24, Zalevsky Jonathan sold 9,014 shares at 0.68 per share. NKTR shares that Chief R&D Officer owns now total 265,025.

Among the insiders who sold shares, Wilson Mark Andrew disposed of 7,606 shares on Feb 20 ’24 at a per-share price of $0.68. This resulted in the Chief Legal Officer holding 236,674 shares of NKTR after the transaction. In another insider transaction, ROBIN HOWARD W sold 19,877 shares at $0.49 per share on Nov 17 ’23. Company shares held by the President & CEO now total 899,922.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, NKTR has a high of $1.12 and a low of $0.41.

As of this writing, NKTR has an earnings estimate of -$0.19 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.17 per share and a lower estimate of -$0.22. The company reported an EPS of -$0.24 in the last quarter, which was -20.00% lower than expectations of -$0.2.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. NKTR’s latest balance sheet shows that the firm has $733.96M in Cash & Short Term Investments as of fiscal 2021. There were $143.18M in debt and $85.20M in liabilities at the time. Its Book Value Per Share was $0.68, while its Total Shareholder’s Equity was $679.51M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NKTR is Buy with a score of 2.50.

Most Popular

Related Posts